ANAVEX LIFE SCIENCES CORP. Cash and Equivalents

Quick Answer

ANAVEX LIFE SCIENCES CORP. reported Cash and Equivalents of $102.58 million for fiscal year 2025.

ANAVEX LIFE SCIENCES CORP. Cash and Equivalents — Annual History

Fiscal Year Cash and Equivalents YoY Change
2025 $102.58M -22.4%
2024 $132.19M -12.5%
2023 $151.02M +1.3%
2022 $149.16M -1.9%
2021 $152.11M +420.0%
2020 $29.25M +31.8%
2019 $22.19M -3.2%
2018 $22.93M -16.4%
2017 $27.44M +198.7%
2016 $9.19M

Quarterly Cash and Equivalents

Quarter Ending Cash and Equivalents YoY QoQ
December 31, 2025 $131.75M +9.1% +28.4%
September 30, 2025 $102.58M -22.4% +1.4%
June 30, 2025 $101.16M -27.1% -12.6%
March 31, 2025 $115.77M -16.9% -4.1%
December 31, 2024 $120.78M -16.0% -8.6%
September 30, 2024 $132.19M -12.5% -4.7%
June 30, 2024 $138.76M -10.4% -0.5%
March 31, 2024 $139.39M -9.2% -3.0%
  • ANAVEX LIFE SCIENCES CORP. showed a decrease of -22.4% in Cash and Equivalents compared to the prior fiscal year.
  • Over the 2016–2025 period, ANAVEX LIFE SCIENCES CORP.’s cash and equivalents has grown by 1016.6% (from $9.19 million to $102.58 million).
  • The most recent figure is from ANAVEX LIFE SCIENCES CORP.’s fiscal year 2025 report (Form 10-K), filed with the SEC on November 25, 2025.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment